Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (1):



(1)

wherein:

A is phenylene;

n is 0, 1 or 2;

m is 0, 1 or 2;

R^1 is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, *N*-(1-4C)alkylcarbamoyl, *N*,*N*-((1-4C)alkyl)$_2$carbamoyl, sulphamoyl, *N*-(1-4C)alkylsulphamoyl, *N*,*N*-((1-4C)alkyl)$_2$sulphamoyl, -S(O)$_b$(1-4C)alkyl (wherein b is 0,1,or 2), -OS(O)$_2$(1-4C)alkyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (1-4C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy and -NHSO$_2$(1-4C)alkyl;

or, when n is 2, the two R^1 groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring, optionally being substituted by one or two methyl groups;

R^4 is independently selected from halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy and (1-4C)alkanoyl;

r is 1 or 2; and

when r is 1 the group



is a substituent on carbon (2) and

when r is 2 (thereby forming a six membered ring) the same group is a substituent on carbon (2) or on carbon (3);

Y is selected from –C(O)R^2, –C(O)OR^2, -C(O)NR^2R^3, -(1-4C)alkyl [optionally substituted by 1 or 2 substituents independently selected from hydroxy, -C=NR^2, (1-4C)alkoxy, aryloxy, -S(O)$_b$$R^2$ (wherein b is 0, 1 or 2), -O-S(O)$_b$$R^2$ (wherein b is 0, 1 or 2), -NR^2R^3, -N(OH)R^2, -NR^2C(=O)R^2, -NHOHC(=O)R^2, -SO_2NR^2R^3, -N(R^2)SO_2R^2 and aryl], -C(O)NOH, -C(O)NSH, -C(N)OH, -C(N)SH, -SO_2H, -SO_3H, -SO_2N(OH)R^2, -(2-4C)alkenyl, -SO_2NR^2R^3, -(1-4C)alkylC(O)R^2, -(1-4C)alkylC(O)OR^2, -(1-4C)alkylSC(O)R^2, -(1-4C)alkylOC(O)R^2, -(1-4C)alkylC(O)NR^2R^3, -(1-4C)alkylOC(O)OR^2, -(1-4C)alkylN(R^2)C(O)OR^2, -(1-4C)alkylN(R^2)C(O)NR^2R^3, -(1-4C)alkylOC(O)NR^2R^3, (3-6C)cycloalkyl (optionally substituted by 1 or 2 R^8), aryl, -(1-4C)alkylSO_2(2-4C)alkenyl and –S(O)$_c$$R^2$ (wherein c is 0, 1 or 2);

R^2 and R^3 are independently selected from hydrogen, -O(1-4C)alkyl, -S(1-4C)alkyl, -N(1-4C)alkyl, aryl and (1-4C)alkyl [optionally substituted by 1 or 2 R^8 groups]; or

R^8 is independently selected from hydrogen, hydroxy, (1-4C)alkyl, (2-4C)alkenyl, (1-4C)alkoxy, cyano(1-4C)alkyl, amino(1-4C)alkyl [optionally substituted on nitrogen by 1 or 2 groups selected from (1-4C)alkyl, hydroxy, hydroxy(1-4C)alkyl, dihydroxy(1-4C)alkyl, -CO_2(1-4C)alkyl, aryl and aryl(1-4C)alkyl], halo(1-4C)alkyl, dihalo(1-4C)alkyl, trihalo(1-4C)alkyl, hydroxy(1-4C)alkyl, dihydroxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkyl, hydroxy(1-4C)alkoxy, aryl, (3-7C)cycloalkyl (optionally substituted with 1 or 2 hydroxy groups, (1-4C)alkyl or -CO_2(1-4C)alkyl), (1-4C)alkanoyl, (1-4C)alkylS(O)$_b$- (wherein b is 0, 1 or 2), (3-6C)cycloalkylS(O)$_b$- (wherein b is 0, 1 or 2), arylS(O)$_b$- (wherein b is 0, 1 or 2), benzylS(O)$_b$- (wherein b is 0, 1 or 2), (1-4C)alkylS(O)$_c$(1-4C)alkyl- (wherein c is 0, 1 or 2), -N(OH)CHO, -C(=N-OH)NH_2, -C(=N-OH)NH(1-4C)alkyl, -C(=N-OH)N((1-4C)alkyl)$_2$, -C(=N-OH)NH(3-6C)cycloalkyl, -C(=N-OH)N((3-6C)cycloalkyl)$_2$, -COCOOR^9, -C(O)N(R^9)(R^{10}), -NHC(O)R^9, -C(O)NHSO_2(1-4C)alkyl, -NHSO_2R^9, (R^9)(R^{10})NSO_2-, -COCH_2OR^{11}, -COCH_2OH, (R^9)(R^{10})N- , -COOR^9, -CH_2OR^9, –CH_2COOR^9, –CH_2OCOR^9, -CH_2CH(CO_2R^9)OH, –CH_2C(O)NR^9R^{10}, -(CH_2)$_w$CH(NR^9R^{10})$CO_2R^{9'}$ (wherein w is 1, 2 or 3), and -(CH_2)$_w$CH(NR^9R^{10})CO(N$R^{9'}R^{10'}$) (wherein w is 1, 2 or 3);

R^9, $R^{9'}$, R^{10} and $R^{10'}$ are independently selected from hydrogen, hydroxy, (1-4C)alkyl (optionally substituted by 1 or 2 R^{11}), (2-4C)alkenyl, (3-7C)cycloalkyl (optionally substituted by 1 or 2 hydroxy groups), cyano(1-4C)alkyl, trihalo(1-4C)alkyl, aryl, $-CO_2$(1-4C)alkyl; or
R^{11} is independently selected from (1-4C)alkyl, and hydroxy(1-4C)alkyl;
or a pharmaceutically acceptable salt ~~or pro-drug~~ thereof.

2. (cancelled)

3. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in claim 1, wherein n is 0.

4 (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in claim 1 wherein r is 1.

5. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in claim 1 wherein m is 1.

6. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in claim 1 wherein Y is selected from $-C(O)OR^2$, $-C(O)NR^2R^3$, -(1-4C)alkyl [optionally substituted by a substituent selected from hydroxy, (1-4C)alkoxy, $-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-O-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-NR^2R^3$, $-NR^2C(=O)R^2$ and $-SO_2NR^2R^3$], -(1-4C)alkylC(O)R^2, -(1-4C)alkylC(O)OR^2, -(1-4C)alkylOC(O)R^2, -(1-4C)alkylC(O)NR^2R^3, -(1-4C)alkylOC(O)OR^2, -(1-4C)alkylN(R^2)C(O)OR^2, -(1-4C)alkylN(R^2)C(O)NR^2R^3, -(1-4C)alkylSC(O)R^2, -(1-4C)alkylOC(O)NR^2R^3, -(1-4C)alkylSO_2(2-4C)alkenyl and $-SO_cR^2$ (wherein c is 0, 1 or 2).

7. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in claim 1 wherein R^2 and R^3 are independently selected from hydrogen, -O(1-4C)alkyl, -N(1-4C)alkyl, (1-4C)alkyl [optionally substituted by 1 or 2 R^8 groups].

8. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in claim 1 wherein R^8 is independently selected

from hydrogen, hydroxy, -C(O)N(R^9)(R^{10}), -NHC(O)R^9, -COOR^9, -CH_2OR^9, –CH_2COOR^9, -CH_2OCOR^9 and aryl.

9. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in claim 1 wherein R^9 and R^{10} are independently selected from hydrogen, hydroxy and (1-4C)alkyl).

10. (currently amended) A pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

11-15 (cancelled)

16. (withdrawn - currently amended) A process for the preparation of a compound of formula (1) as claimed in claim 1, which process comprises:
reacting an acid of the formula (2):



(2)

or an activated derivative thereof; with an amine of formula (3):



(3)

and thereafter if necessary:
i) converting a compound of the formula (1) into another compound of the formula (1);
ii) removing any protecting groups;
iii) forming a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~.

17. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt ~~or in-vivo hydrolysable ester~~ thereof, as claimed in claim 1 wherein R^4 is selected from chloro, fluoro and methyl.

18. (previously presented) A compound of the formula (I) wherein
A is phenylene;
n is 0;
m is 1;
R^4 is chloro;
Y is selected from –C(O)OR^2, -C(O)NR^2R^3, -(1-4C)alkyl [optionally substituted by a substituent selected from -S(O)$_b$$R^2$ (wherein b is 0, 1 or 2), -O-S(O)$_b$$R^2$ (wherein b is 0, 1 or 2), -NR^2R^3, -NR^2C(=O)R^2 and -SO_2NR^2R^3], -(1-4C)alkylC(O)OR^2, -(1-4C)alkylOC(O)R^2, -(1-4C)alkylC(O)NR^2R^3 , -(1-4C)alkylSC(O)R^2, -(1-4C)alkylSO_2(2-4C)alkenyl and -$SO_c$$R^2$ (wherein c is 0, 1 or 2);
R^2 and R^3 are independently selected from hydrogen and (1-4C)alkyl [optionally substituted by 1 or 2 R^8 groups];
R^8 is independently selected from hydrogen, hydroxy, -C(O)N(R^9)(R^{10}), -NHC(O)R^9, -COOR^9 and aryl;
R^9 and R^{10} are independently selected from hydrogen, hydroxy and (1-4C)alkyl).

19. (previously presented) A compound of the formula (I) selected from
Methyl (1*R*,2*R*)-2-{[(5-chloro-1*H*-indole-2-yl)carbonyl]amino}indane-1-carboxylate;
5-Chloro-*N*-[(1*R*,2*R*)-1-(hydroxymethyl)-2,3-dihydro-1*H*-inden-2-yl]-indole-2-carboxamide;
(1*R*,2*R*)-2-{[(5-chloro-1*H*-indole-2-yl)carbonyl]amino}indane-1-carboxylic acid;
5-Fluoro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;
N-[(1*R*,2*R*)-1-({[(2-Hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-5-methyl-1*H*-indole-2-carboxamide;
N-[(1*R*,2*R*)-1-({[(2-Hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;
5-Chloro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;
5-Fluoro-*N*-((1*R*,2*R*)-1-{[(3-hydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

N-((1*R*,2*R*)-1-{[(3-Hydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-5-methyl-1*H*-indole-2-carboxamide;
N-((1*R*,2*R*)-1-{[(3-Hydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;
5-Chloro-*N*-((1*R*,2*R*)-1-{[(3-hydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;
[((1*R*,2*R*)-2-{[(5-Chloro-1*H*-indol-2-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)thio]acetic acid;
Methyl [((1*R*,2*R*)-2-{[(5-chloro-1*H*-indol-2-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)thio]acetate;
5-Fluoro-*N*-((1*R*,2*R*)-1-{[(2-hydroxyethyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;
5-Chloro-*N*-((1*R*,2*R*)-1-{[(2-hydroxyethyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;
N-((1*R*,2*R*)-1-{[(2-Hydroxyethyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-5-methyl-1*H*-indole-2-carboxamide;
N-((1*R*,2*R*)-1-{[(2-Hydroxyethyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide; and
N-{(1*R*,2*R*)-1-[(2-Amino-2-oxoethyl)thio]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide.

20. (withdrawn) A method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

21. (withdrawn) A method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

22. (withdrawn) A method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.